Company intelligence / Profile preview

PathogenDx

Scottsdale, Arizona, United States

Ownership: Private
Development stage: Other

Overview

PathogenDx has commercialized its D3 Array platform technology for pathogen detection across multiple markets. The company's COVID-19 test (DetectX-Cv+) received Emergency Use Authorization in April 2021 and CE marking in February 2022. The EnviroX-F assay received AOAC Performance Tested Method Status in October 2020 for multiplex detection of Salmonella spp., Listeria spp., and L. monocytogenes. The D3 Array-UTI test was recognized with the 2024 Frost & Sullivan North American New Product Innovation Award for UTI detection, capable of identifying 26 pathogens and 12 antibiotic resistance genes.

Therapeutic areas: Infectious Diseases
Industry: Molecular Diagnostics

Partnerships

Formula DiagnosticsBashas' Food City

Beyond the preview

Go deeper on PathogenDx.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PathogenDx.

Explore the full profile